Functional imaging of head and neck tumors using positron emission tomography.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Functional imaging of head and neck tumors using positron emission tomography. / Zeitouni, A G; Yamamoto, Y L; Black, M; Gjedde, A.

In: Journal of Otolaryngology, Vol. 23, No. 2, 1994, p. 77-80.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Zeitouni, AG, Yamamoto, YL, Black, M & Gjedde, A 1994, 'Functional imaging of head and neck tumors using positron emission tomography.', Journal of Otolaryngology, vol. 23, no. 2, pp. 77-80.

APA

Zeitouni, A. G., Yamamoto, Y. L., Black, M., & Gjedde, A. (1994). Functional imaging of head and neck tumors using positron emission tomography. Journal of Otolaryngology, 23(2), 77-80.

Vancouver

Zeitouni AG, Yamamoto YL, Black M, Gjedde A. Functional imaging of head and neck tumors using positron emission tomography. Journal of Otolaryngology. 1994;23(2):77-80.

Author

Zeitouni, A G ; Yamamoto, Y L ; Black, M ; Gjedde, A. / Functional imaging of head and neck tumors using positron emission tomography. In: Journal of Otolaryngology. 1994 ; Vol. 23, No. 2. pp. 77-80.

Bibtex

@article{ed5cbfd0b31411debc73000ea68e967b,
title = "Functional imaging of head and neck tumors using positron emission tomography.",
abstract = "Positron emission tomography (PET) is an imaging modality that generates in vivo maps of tissue radioactivity originating from a labelled substrate of glucose metabolism: 18-fluorine labelled deoxy-glucose (FDG). This study was undertaken to evaluate PET in the detection of head and neck malignancies, and to determine its effectiveness in diagnosing recurrent cancer in operated or irradiated fields. PET revealed that each biopsy-proven tumour is an area of increased radioactivity. Tumour radioactivity ranged from 130% to 300% above that of the cerebellum, and up to 650% above the contralateral, normal side. By basing the maps on tissue metabolic function, PET proved capable of distinguishing tumour (increased radioactivity) from scar tissue (reduced radioactivity). Its application may facilitate the diagnosis of recurrent tumours amid the fibrosis and distortion of normal architecture in operated, irradiated fields.",
author = "Zeitouni, {A G} and Yamamoto, {Y L} and M Black and A Gjedde",
year = "1994",
language = "English",
volume = "23",
pages = "77--80",
journal = "Journal of Otolaryngology - Head and Neck Surgery",
issn = "1916-0208",
publisher = "B.C./Decker Inc",
number = "2",

}

RIS

TY - JOUR

T1 - Functional imaging of head and neck tumors using positron emission tomography.

AU - Zeitouni, A G

AU - Yamamoto, Y L

AU - Black, M

AU - Gjedde, A

PY - 1994

Y1 - 1994

N2 - Positron emission tomography (PET) is an imaging modality that generates in vivo maps of tissue radioactivity originating from a labelled substrate of glucose metabolism: 18-fluorine labelled deoxy-glucose (FDG). This study was undertaken to evaluate PET in the detection of head and neck malignancies, and to determine its effectiveness in diagnosing recurrent cancer in operated or irradiated fields. PET revealed that each biopsy-proven tumour is an area of increased radioactivity. Tumour radioactivity ranged from 130% to 300% above that of the cerebellum, and up to 650% above the contralateral, normal side. By basing the maps on tissue metabolic function, PET proved capable of distinguishing tumour (increased radioactivity) from scar tissue (reduced radioactivity). Its application may facilitate the diagnosis of recurrent tumours amid the fibrosis and distortion of normal architecture in operated, irradiated fields.

AB - Positron emission tomography (PET) is an imaging modality that generates in vivo maps of tissue radioactivity originating from a labelled substrate of glucose metabolism: 18-fluorine labelled deoxy-glucose (FDG). This study was undertaken to evaluate PET in the detection of head and neck malignancies, and to determine its effectiveness in diagnosing recurrent cancer in operated or irradiated fields. PET revealed that each biopsy-proven tumour is an area of increased radioactivity. Tumour radioactivity ranged from 130% to 300% above that of the cerebellum, and up to 650% above the contralateral, normal side. By basing the maps on tissue metabolic function, PET proved capable of distinguishing tumour (increased radioactivity) from scar tissue (reduced radioactivity). Its application may facilitate the diagnosis of recurrent tumours amid the fibrosis and distortion of normal architecture in operated, irradiated fields.

M3 - Journal article

C2 - 8028075

VL - 23

SP - 77

EP - 80

JO - Journal of Otolaryngology - Head and Neck Surgery

JF - Journal of Otolaryngology - Head and Neck Surgery

SN - 1916-0208

IS - 2

ER -

ID: 14942450